Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04712760
Other study ID # 2020PI260
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 22, 2021
Est. completion date April 1, 2021

Study information

Verified date February 2021
Source Central Hospital, Nancy, France
Contact Emeline Renard, MD
Phone +33 3 83 15 45 00
Email e.renard@chru-nancy.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In France, the incidence of congenital hypothyroidism has increased significantly since the newborn screening program was introduced in 1978. The largest increase is seen in children with eutopic thyroid gland. More than one-third of children with eutopic gland have transient hypothyroidism. Clinical practice guidelines recommend to re-evaluate thyroid function in children with eutopic gland around the age of 3 years to determine whether hypothyroidism is transient or permanent. Up until today it is still difficult to determine early on whether hypothyroidism is transient or permanent in children with eutopic gland. Our aim is to identify one or more predictive factors for transient congenital hypothyroidism in children with eutopic gland or thyroid hemiagenesis.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date April 1, 2021
Est. primary completion date March 1, 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 42 Months
Eligibility Inclusion Criteria: - Children with congenital hypothyroidism - Eutopic thyroid gland or thyroid hemiagenesis - Born between 1996 and 2017 - Treated at the Nancy Regional and University Hospital - Follow-up of at least 3,5 years. Exclusion Criteria: - Polymalformative syndrome - Thyroid dysgenesis except for thyroid hemiagenesis

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CHRU Nancy Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identify one or more predictive factors for transient congenital hypothyroidism in children with eutopic gland or thyroid hemiagenesis. 42 months
Secondary Compare the dose of Levothyroxine between children with transient and permanent congenital hypothyroidism at 6 months, 1 year, 2 years and 3 years follow-up. 6 months, 1 year, 2 years, 3 years
Secondary Assess the percentage of children with psychomotor impairment at the age of 3,5 years in both groups. 42 months
Secondary Assess how many children have had a hearing evaluation in both groups (excluding the newborn hearing screening). 42 months
See also
  Status Clinical Trial Phase
Withdrawn NCT01223638 - The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism N/A
Completed NCT01916018 - Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT02307175 - A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication N/A
Completed NCT00497575 - Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT00403390 - Generic vs. Name-Brand Levothyroxine N/A
Not yet recruiting NCT04734457 - Final Height in Patients With CH Diagnosed by the Screening
Completed NCT05371262 - Influence of Initial Levothyroxine Dose on Neurodevelopmental and Growth Outcomes in Congenital Hypothyroidism Phase 4
Recruiting NCT00505479 - Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy? N/A
Completed NCT02374593 - Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism N/A
Completed NCT00493103 - TG Gene Mutations and Congenital Hypothyroidism N/A
Active, not recruiting NCT05228184 - Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH) Phase 4
Completed NCT01488721 - Clinical Evaluation of NeoPlex4 Assay and NeoPlex System N/A